---
layout: default
title: Tramadol
parent: Model Prediction Only (L5)
nav_order: 920
evidence_level: L5
indication_count: 10
---

# Tramadol
{: .fs-9 }

Evidence Level: **L5** | Predicted Indications: **10** 
{: .fs-6 .fw-300 }

---

## Table of Contents
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## Pharmacist Assessment Report

</div>

# Tramadol: From Pain Management to Acromesomelic Dysplasia, Hunter-Thompson Type

## One-Sentence Summary

Tramadol is an opioid analgesic marketed in Canada, generally used for moderate to moderately severe pain. The TxGNN model predicts it may be effective for **acromesomelic dysplasia, Hunter-Thompson type**, a rare genetic skeletal disorder. **No clinical trials and no publications** currently support this prediction, so it is a model output only.

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Pain management (general drug knowledge; the Canadian licence records supplied contain no indication text) |
| Predicted New Indication | Acromesomelic dysplasia, Hunter-Thompson type |
| TxGNN Prediction Score | 99.99% |
| Evidence Level | L5 |
| Canada Market Status | ✓ Marketed |
| Number of DINs | 20 |
| Recommended Decision | Hold |

## Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in the Evidence Pack. Tramadol is generally known as a mu-opioid receptor agonist with serotonin and norepinephrine reuptake inhibition, and its efficacy in pain is established.

Based on the evidence reviewed, **the prediction is not mechanistically credible**. Acromesomelic dysplasia, Hunter-Thompson type, is a genetic skeletal dysplasia involving the CDMP1/GDF5 pathway, which controls cartilage and bone growth. Tramadol's analgesic pharmacology does not act on chondrogenesis or bone growth. The very high score (rank 285 in the model's output) most likely reflects a knowledge-graph association rather than a real biological link.

The other nine top-ranked predictions show the same pattern. They are skeletal dysplasias (brachyolmia, pseudoachondroplasia) and rheumatologic conditions (juvenile idiopathic arthritis, rheumatoid nodulosis, spondyloarthropathy). At most, tramadol could give symptomatic pain relief in some of them, and it would not modify the disease. Pediatric opioid safety is an additional concern for the juvenile arthritis predictions.

## Clinical Trial Evidence

Currently no related clinical trials registered.

## Literature Evidence

Currently no related literature available.

## Canada Market Information

| DIN | Product Name | Dosage Form | Approved Indication |
|---------|------|------|-----------|
| 2286459 | ZYTRAM XL | Not provided | Not provided |
| 2286440 | ZYTRAM XL | Not provided | Not provided |
| 2518759 | JAMP TRAMADOL HCL | Not provided | Not provided |
| 2480859 | MAR-TRAMADOL | Not provided | Not provided |
| 2373033 | DURELA | Not provided | Not provided |

These are 5 of the 20 licences.

## Safety Considerations

Please refer to the package insert for safety information. No warnings, contraindications, or drug interaction records were retrieved.

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The prediction rests on the model score alone (L5), with no trials or literature. There is also no plausible mechanism linking tramadol's analgesic action to a GDF5-pathway skeletal dysplasia. Safety data are missing as well.

**To proceed, the following is needed:**
- Health Canada package insert warnings and contraindications (this blocks safety screening)
- Mechanism of action data from DrugBank to support any mechanistic analysis
- Approved indication text and dosage forms for the Canadian licences
- Any preclinical or clinical evidence linking tramadol to the GDF5/CDMP1 pathway or to this disease. Without it, this candidate should not advance.
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

